The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis

References

• Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022 Jan;183:109119.
   Google Scholar
• Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012 Mar;35(3):556–564.
   Google Scholar
• Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021 Nov;128(11):1580–1591.
   Google Scholar
• Solomon SD, Chew E, and Duh EJ, et al. Diabetic retinopathy: a position statement by the American Diabetes Association. Diabetes Care. 2017 Mar;40(3):412–418.
   Google Scholar
• Ting DS, Cheung GC, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 2016 May;44(4):260–277.
   Google Scholar
• Silva PS, Cavallerano JD, Sun JK, et al. Effect of systemic medications on onset and progression of diabetic retinopathy. Nat Rev Endocrinol. 2010 Sep;6(9):494–508.
   Google Scholar
• Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016 Jan 30;387(10017):435–443.
   Google Scholar
• Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017 Jun;5(6):431–437.
   Google Scholar
• Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 Oct;16(10):556–577.
   Google Scholar
• Leley SP, Luo Q, Alex AL, et al. 588-P: diabetes leads to sodium-glucose cotransporter 2 (SGLT2) increase in the retina. Diabetes. 2019;68:1.
   Google Scholar
• Matthews J, Herat L, and Rooney J, et al. Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy. Biosci Rep. 2022;42(3). DOI:10.1042/BSR20212209.
   Google Scholar
• Takakura S, Toyoshi T, Hayashizaki Y, et al. Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats. Life Sci. 2016 Feb 15;147:125–131.
   Google Scholar
• Hanaguri J, Yokota H, and Kushiyama A, et al. The effect of sodium-dependent glucose cotransporter 2 inhibitor tofogliflozin on neurovascular coupling in the retina in Type 2 diabetic mice. Int J Mol Sci. 2022;23(3):1362.
   Google Scholar
• Ott C, Jumar A, Striepe K, et al. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovasc Diabetol. 2017 Feb 23;16(1):26.
   Google Scholar
• Fernandes VHR, Chaves FRP, and Soares AAS, et al. Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: a randomized controlled trial. Diabetes Metab. 2021 Nov;47(6):101280.
   Google Scholar
• Sabaner MC, Duman R, Dogan M, et al. Do SGLT2 inhibitors prevent preclinical diabetic retinopathy? A prospective pilot optical coherence tomography angiography study. J Fr Ophtalmol. 2021 Oct;44(8):1159–1167.
   Google Scholar
• Dziuba J, Alperin P, Racketa J, et al. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab. 2014 Jul;16(7):628–635.
   Google Scholar
• Inzucchi SE, Wanner C, and Hehnke U, et al. Retinopathy outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. Diabetes Care. 2019 Apr;42(4):e53–e55.
   Google Scholar
• Tang H, Li G, Zhao Y, et al. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: a network meta-analysis. Diabetes Obes Metab. 2018 May;20(5):1262–1279.
   Google Scholar
• Li C, Zhou Z, and Neuen BL, et al. Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2021 Jan;23(1):252–257.
   Google Scholar
• Sha W, Wen S, and Chen L, et al. The Role of SGLT2 inhibitor on the treatment of diabetic retinopathy. J Diabetes Res. 2020;2020:8867875.
   Google Scholar
• Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011 Sep;30(5):343–358.
   Google Scholar
• Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 2018 Dec;44(6):457–464.
   Google Scholar
• Koufakis T, Vas P, Maltese G, et al. Antiatherosclerotic effects of sodium-glucose cotransporter 2 inhibitors: an underrecognized piece of the big puzzle? J Clin Endocrinol Metab. 2022 Mar 5. 10.1210/clinem/dgac116.
   Google Scholar
• Ellis TP, Choudhury RH, Kaul K, et al. Diabetic retinopathy and atherosclerosis: is there a link? Curr Diabetes Rev. 2013 Mar 1;9(2):146–160.
   Google Scholar
• Matthews VB, Elliot RH, Rudnicka C, et al. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens. 2017 Oct;35(10):2059–2068.
   Google Scholar
• Herat LY, Matthews VB, Rakoczy PE, et al. Focusing on sodium glucose cotransporter-2 and the sympathetic nervous system: potential impact in diabetic retinopathy. Int J Endocrinol. 2018;2018:9254126.
   Google Scholar
• Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977–986.
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 Sep 12;352(9131): 837–853.
   Google Scholar
• Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010 Jul 15;363(3):233–244.
   Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2560–2572.
   Google Scholar
• Bain SC, Klufas MA, Ho A, et al. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review. Diabetes Obes Metab. 2019 Mar;21(3):454–466.
   Google Scholar
• Wong TY, Cheung CM, Larsen M, et al. Diabetic retinopathy. Nat Rev Dis Primers. 2016 Mar;2(1):16012.
   Google Scholar
• Shah S, Feher M, McGovern A, et al. Diabetic retinopathy in newly diagnosed Type 2 diabetes mellitus: prevalence and predictors of progression; a national primary network study. Diabetes Res Clin Pract. 2021 May;175:108776.
   Google Scholar
• Kostev K, Rathmann W. Diabetic retinopathy at diagnosis of type 2 diabetes in the UK: a database analysis. Diabetologia. 2013 Jan;56(1):109–111.
   Google Scholar
• Ponto KA, Koenig J, Peto T, et al. Prevalence of diabetic retinopathy in screening-detected diabetes mellitus: results from the Gutenberg Health Study (GHS). Diabetologia. 2016 Sep;59(9):1913–1919.
   Google Scholar
• Chung YR, Ha KH, Lee K, et al. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: a real-world Korean study. PLoS One. 2019;14(10):e0224549.
   Google Scholar
• Zhang Y, Nakano D, Guan Y, et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int. 2018 Sep;94(3):524–535.
   Google Scholar
• Antonetti DA, Silva PS, Stitt AW. Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nat Rev Endocrinol. 2021 Apr;17(4):195–206.
   Google Scholar
• Simó R, Sundstrom JM, Antonetti DA. Ocular Anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care. 2014 Apr;37(4):893–899.
   Google Scholar
• Wakisaka M, Kitazono T, Kato M, et al. Sodium-coupled glucose transporter as a functional glucose sensor of retinal microvascular circulation. Circ Res. 2001 Jun 8;88(11):1183–1188.
   Google Scholar
• Farioli A, Hemmingsson T, Kriebel D. Vascular risk factors and rhegmatogenous retinal detachment: a follow-up of a national cohort of Swedish men. Br J Ophthalmol. 2016 Jul;100(7):907–913.
   Google Scholar
• Cheung N, Wong TY. Obesity and eye diseases. Surv Ophthalmol. 2007 Mar-Apr;52(2):180–195.
   Google Scholar
• Gange WS, Lopez J, Xu BY, et al. Incidence of proliferative diabetic retinopathy and other neovascular sequelae at 5 years following diagnosis of Type 2 diabetes. Diabetes Care. 2021 Nov;44(11):2518–2526.
   Google Scholar
• Zhu W, Wu Y, Meng YF, et al. Association of obesity and risk of diabetic retinopathy in diabetes patients: a meta-analysis of prospective cohort studies. Medicine (Baltimore). 2018 Aug;97(32):e11807.
   Google Scholar
• Do DV, Wang X, Vedula SS, et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev. 2015 Jan;31(1):Cd006127.
   Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Bmj.1998 Sep 12;317(7160):703–713.
   Google Scholar
• Sjølie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008 Oct 18;372(9647):1385–1393.
   Google Scholar
• Sjølie AK, Dodson P, Hobbs FR. Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review. Int J Clin Pract. 2011 Feb;65(2):148–153.
   Google Scholar
• Ansary TM, Nakano D, Nishiyama A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mol Sci. 2019;20(3):629.
   Google Scholar
• Kitazawa M, Katagiri T, Suzuki H, et al. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: the N-ISM study. Diabetes Obes Metab. 2021 Mar;23(3):811–821.
   Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295–2306.
   Google Scholar
• Modjtahedi BS, Bose N, Papakostas TD, et al. Lipids and diabetic retinopathy. Semin Ophthalmol. 2016;31(1–2):10–18.
   Google Scholar
• Chen YH, Chen HS, Tarng DC. More impact of microalbuminuria on retinopathy than moderately reduced GFR among type 2 diabetic patients. Diabetes Care. 2012 Apr;35(4):803–808.
   Google Scholar
• Yang JK, Liu W, Shi J, et al. An association between subclinical hypothyroidism and sight-threatening diabetic retinopathy in type 2 diabetic patients. Diabetes Care. 2010 May;33(5):1018–1020.
   Google Scholar